Connection

Robert Clifford to Antibodies, Neutralizing

Back to Details
This is a "connection" page, showing publications Robert Clifford has written about Antibodies, Neutralizing.
Robert Clifford
Connection Strength
0.157
Antibodies, Neutralizing
  1. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial. Lancet Infect Dis. 2024 Jul; 24(7):687-697.
    View in: PubMed
    Score: 0.057
  2. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. N Engl J Med. 2022 Nov 03; 387(18):1673-1687.
    View in: PubMed
    Score: 0.051
  3. Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age. N Engl J Med. 2022 05 26; 386(21):2011-2023.
    View in: PubMed
    Score: 0.050
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.